Prothena to Report Third Quarter 2020 Financial Results on November 4
October 28 2020 - 4:05PM
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical
company with expertise in protein dysregulation and a diverse
pipeline of investigational therapeutics for neurodegenerative and
rare peripheral amyloid diseases, announced today that it will
report its third quarter and first nine months of 2020 financial
results on Wednesday, November 4, after the close of the U.S.
financial markets.
Consistent with past practice, the Company will
not be conducting a conference call in conjunction with this
financial results release on November 4.
About Prothena
Prothena Corporation plc is a late-stage
clinical company with expertise in protein dysregulation and a
diverse pipeline of novel investigational therapeutics with the
potential to change the course of devastating neurodegenerative and
rare peripheral amyloid diseases. Fueled by its deep scientific
expertise built over decades of research, Prothena is advancing a
pipeline of therapeutic candidates for a number of indications and
novel targets for which its ability to integrate scientific
insights around neurological dysfunction and the biology of
misfolded proteins can be leveraged. Prothena’s partnered programs
include prasinezumab (PRX002/RG7935), in collaboration with Roche
for the potential treatment of Parkinson’s disease and other
related synucleinopathies, and programs that target tau (PRX005),
TDP-43, and an undisclosed target in collaboration with
Bristol-Myers Squibb for the potential treatment of Alzheimer’s
disease, amyotrophic lateral sclerosis (ALS), frontotemporal
dementia (FTD) or other neurodegenerative diseases. Prothena’s
proprietary programs include PRX004 for the potential treatment of
ATTR amyloidosis, and a portfolio of programs for the potential
treatment of Alzheimer’s disease including PRX012 that targets Aβ
(Amyloid beta). For more information, please visit the Company’s
website at www.prothena.com and follow the Company on Twitter
@ProthenaCorp.
Contacts:
MediaEllen Rose, Head of
Communications650-922-2405, ellen.rose@prothena.com
InvestorsJennifer Zibuda,
Director, Investor Relations & Communications650-837-8535,
jennifer.zibuda@prothena.com
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prothena (NASDAQ:PRTA)
Historical Stock Chart
From Apr 2023 to Apr 2024